N/A N=12,386 Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=140 Medication Adherence in Individuals With Epilepsy
Epilepsy
Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days
Phase 2 N=11 Pilot Study of Melatonin and Epilepsy
Epilepsy
Primary: Sleep Latency Wakefulness After Sleep Onset (WASO) — 42.3; 57.3 minutes/night
Phase 2 N=126 Levetiracetam to Prevent Post-Traumatic Epilepsy
Epilepsy · Post-traumatic Epilepsy
Primary: Post-Traumatic Epilepsy — 6; 8 participants
N/A N=1,672 Bridging the Childhood Epilepsy Treatment Gap in Africa
Epilepsy
Primary: Percentage Seizure-free for 6 Months, or Longer, Measured at 24 Months After Enrollment — 371; 299 Participants — p=0.11
Phase 4 N=51 Methylphenidate Treatment of Attention Deficits in Epilepsy
Epilepsy · Cognitive Deficits · Attention Deficits
Primary: Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables) — -3.3; -3.58; -3.66; 0.19 Units — p=0.037
N/A N=29 Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
Epilepsy
Primary: The Change Scores in Memory Measures From Baseline to Post-treatment/Placebo Will be Compared Between the Memantine Treatment and Placebo Groups. — 1.00; 1.78; 4.38…
N/A N=2 Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy
Uncontrolled Partial Epilepsy · Ictal Hypoventilation
Primary: The Primary End Point for This Study is a 50% Fluoxetine-related Reduction in the Number of Seizures With Associated Oxygen Desaturations Below 90% Compared With Placebo.
Phase 4 N=52 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy
Partial Epilepsy
Primary: Change in Epworth Sleepiness Scale Score From Baseline to Visit 4 — -1.2; -1.1 Units on a scale — p=0.027
Phase 3 N=64 A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
Epilepsy
Primary: The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline — -32.7; -35.6 percent change — p=0.240
N/A N=21 Steps for Epilepsy
Epilepsy
Primary: Proportion of Participants Who Achieve Their Assigned Step Goal - Adherence — 0.267 Proportion
Phase 4 N=35 Lamotrigine Bioequivalence
Epilepsy
Primary: AUC — 101346; 101393 ng*hr/ml
Phase 2 N=147 A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
Phase 2 N=5 Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Lipodystrophy
Primary: Change in Log 10 Fasting Triglycerides. — 0.1; -0.2 log 10 mg/dl
N/A N=11 To Assess the Utility of the Point Partial in a Clinical Take-home Study of Partial Hand Amputees
Amputation; Traumatic, Hand
Primary: Capacity Assessment of Prosthetic Performance for the Upper Limb (CAPPFUL) — 90.3 score on a scale